Genentech is teaming up with Bicycle Therapeutics to develop cancer immunotherapies. Bicycle uses chemical scaffolds to turn linear peptides into two pretzel-like loops. The firm says these so-called bicyclic peptides can be used as drugs alone or to deliver toxic payloads to cancer cells. Bicycle has several cancer drug programs of its own. Genentech will pay Bicycle $30 million up front—and up to $1.7 billion in milestone payments—to develop bicyclic peptides against several new targets.

    10.1021/cen-09809-buscon18-bicycle-gr1

    Bicycle's bicyclic peptides can be linked to anticancer toxins. (Credit: Bicycle/C&EN)

    Bicyclic peptidesimmunotherapyAn image of Bicycle's bicyclic peptide.


    Access

    Check access

    Check availability in my library

    Order at Subito €


    Export, share and cite



    Title :

    Genentech strikes deal with Bicycle


    Published in:

    Publication date :

    2020-03-09




    Type of media :

    Article (Journal)


    Type of material :

    Electronic Resource


    Language :

    Unknown